Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 7, 2026; 32(25): 119434
Published online Jul 7, 2026. doi: 10.3748/wjg.119434
Published online Jul 7, 2026. doi: 10.3748/wjg.119434
Comparing fexuprazan and rabeprazole for treating peptic ulcer: A multicenter, randomized controlled trial
Dong Soo Lee, Seung Woo Lee, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 03083, South Korea
Sun Hyung Kang, Hee Seok Moon, Jae Kyu Sung, Ju Seok Kim, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, South Korea
Sae Hee Kim, Department of Internal Medicine, Yuseong Sun Medical Center, Daejeon 34084, South Korea
Dong Kyu Lee, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon 35233, South Korea
Ki Bae Kim, Department of Internal Medicine, Chungbuk National University School of Medicine, Cheongju 28644, South Korea
Sun Moon Kim, Department of Internal Medicine, Konyang University College of Medicine, Daejeon 35365, South Korea
Young Sin Cho, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, South Korea
Author contributions: Kim JS and Lee DS designed the study; Lee DS, Lee SW, Kang SH, Moon HS, Sung JK, Kim SH, Lee DK, Kim KB, Kim SM, Cho YS, and Kim JS performed data acquisition, statistical analysis, interpretation of data, and drafting of the manuscript; Lee DS revised the manuscript for important intellectual content; Kim JS supervised the project; all authors read and approved the final manuscript and contributed to the article and approved the submitted version.
Supported by Daewoong Pharmaceutical Co., Ltd. (Seoul, Korea).
Institutional review board statement: This study was approved by the Institutional Review Board of Chungnam National University Sejong Hospital (Approval No. CNUSH IRB 2023-02-020-001).
Clinical trial registration statement: The clinical trial was registered at Cris.nih.go.kr (KCT0008647).
Informed consent statement: All enrolled patients participated in the study after providing informed consent.
Conflict-of-interest statement: There is no potential conflict of interest relevant to this article was reported.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No additional data are available.
Corresponding author: Ju Seok Kim, Department of Internal Medicine, Chungnam National University College of Medicine, 282 Munhwa-ro, Jung-Gu, Daejeon 35015, South Korea.
Received: January 28, 2026
Revised: March 17, 2026
Accepted: April 9, 2026
Published online: July 7, 2026
Processing time: 154 Days and 8.3 Hours
Revised: March 17, 2026
Accepted: April 9, 2026
Published online: July 7, 2026
Processing time: 154 Days and 8.3 Hours
Core Tip
Core Tip: Fexuprazan, a novel potassium-competitive acid blocker, has several advantages compare to proton pump inhibitors. Fexuprazan 40 mg showed non-inferiority in ulcer healing rate after 8 weeks in patients with peptic ulcer disease compared to rabeprazole 20 mg.